Navigation Links
EntreMed to Present at the New York Society of Security Analysts Industry Conference

ROCKVILLE, Md., Nov. 25 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, announced today that a Company overview will be provided at the NYSSA 2008 Biotech and Specialty Pharmaceuticals Industry Conference, to be held at the Conference Facilities at the NYSSA, New York, December 2, 2008. Dane R. Saglio, Chief Financial Officer, will present on behalf of the Company. The presentation is scheduled for 1:35 p.m. (local time) and will be included in an archived web cast on the NYSSA web site after December 3, 2008. An electronic version of Mr. Saglio's presentation will be available on the Company's web site at


About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. MKC-1, an oral cell-cycle regulator with activity against the mTOR pathway, is currently in multiple Phase 2 clinical trials for cancer. ENMD-2076, a selective angiogenic kinase inhibitor, and ENMD-1198, a novel antimitotic agent are in Phase 1 studies in advanced cancers. The Company also has an approved IND application for Panzem(R) in rheumatoid arthritis. EntreMed's goal is to develop and commercialize new compounds based on the Company's expertise in angiogenesis, cell cycle regulation, cell signaling and inflammation - processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the Company's web site at and in various filings with the Securities and Exchange Commission.

    Ginny Dunn
    Associate Director
    Corporate Communications & Investor Relations
    EntreMed, Inc.

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. EntreMeds MKC-1 Meets Primary Efficacy Endpoint in Non-Small Cell Lung Cancer Clinical Trial
2. EntreMed Reports Third Quarter 2008 Financial Results
3. EntreMeds ENMD-2076 Demonstrates Tumor Regression in Human Colon Cancer Model
4. EntreMed to Present at BioPartnering Europe Conference
5. EntreMed Announces Stock Listing Transfer to Nasdaq Capital Market
6. EntreMed Reports Second Quarter 2008 Financial Results
7. EntreMed Appoints Thomas H. Bliss as Senior Vice President of Corporate and Business Development
8. Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMeds Selective Kinase Inhibitor
9. EntreMed Will Not Seek Shareholder Approval for Reverse Stock Split at Annual Meeting
10. EntreMeds Kinase Inhibitor, ENMD-2076, Presented During AACR Special Session
11. EntreMed Receives Nasdaq Deficiency Notice
Post Your Comments:
(Date:11/24/2015)... -- --> --> ... Market by Product & Services (Primer, Probe, Custom Oligos, ... End-User (Research, Pharmaceutical & Biotech, Diagnostic Labs) - Global ... expected to reach USD 1,918.6 Million by 2020 from ... 10.1% during the forecast period. Browse 183 ...
(Date:11/24/2015)...  Tikcro Technologies Ltd. (OTCQB: TIKRF) today announced that its Annual General ... a.m. Israel time, at the law offices of ... 36 th Floor, Tel Aviv, Israel . ... Izhak Tamir to the Board of Directors; , election ... , approval of an amendment to certain terms of options granted to ...
(Date:11/24/2015)... ... November 24, 2015 , ... Creation Technologies ... being named to Deloitte's 2015 Technology Fast 500 list of the fastest growing ... a FDA-cleared, Class II medical device that speeds up orthodontic tooth movement by ...
(Date:11/24/2015)... MUNICH and NEW YORK , ... irst investment by Bristol-Myers Squibb in a ... Bristol-Myers Squibb Company in which the companies ... products in immuno-oncology and other areas of unmet medical need. ... Squibb in LSP 5, the latest LSP fund. This is ...
Breaking Biology Technology:
(Date:11/9/2015)... , Nov. 9, 2015  Synaptics Inc. (NASDAQ: ... today announced broader entry into the automotive market with ... match the pace of consumer electronics human interface innovation. ... are ideal for the automotive industry and will be ... Europe , Japan ...
(Date:10/29/2015)... Daon, a global leader in mobile biometric ... new version of its IdentityX Platform , IdentityX ... have already installed IdentityX v4.0 and are ... FIDO UAF certified server component as an option ... features. These customers include some of the largest and ...
(Date:10/27/2015)... , Oct. 27, 2015 In the present ... of concern for various industry verticals such as banking, ... to the growing demand for secure & simplified access ... ,sectors, such as hacking of bank accounts, misuse of ... equipment such as PC,s, laptops, and smartphones are expected ...
Breaking Biology News(10 mins):